SEARCH

SEARCH BY CITATION

References

  • 1
    Cadwell SH, Oelsnerr DH, Iezzoni JC, Hesplenheide EE, Battle EH, Driscoll C. Cryptogenic cirrhosis clinical characterization and risk factors for underlying disease. HEPATOLOGY 1999; 29: 664669.
  • 2
    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 12211231.
  • 3
    McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002; 34: 255262.
  • 4
    Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134140.
  • 5
    Menders FD, Suzuki A, Angulo P. Prevalence and indicators of portal hypertension in non-alcoholic fatty liver disease. Gastroenterology 2004; 126: A759.
  • 6
    Adams LA, Lymp JF, Sauver ST, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of non-alcoholic fatty liver disease: a population based cohort study. Gastroenterology 2005; 129: 113121.
  • 7
    Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long term follow-up of patients with NAFLD and elevated liver enzymes. HEPATOLOGY 2006; 44: 865873.
  • 8
    Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. Nonalcoholic steatohepatitis and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. HEPATOLOGY 2002; 35: 373379.
  • 9
    Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. HEPATOLOGY 2003; 37: 917923.
  • 10
    Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005; 90: 15781582.
  • 11
    Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle age men. JAMA 2002; 288: 27092716.
  • 12
    Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna RC, et al. Carotid atherosclerosis and coronary hearth disease in the metabolic syndrome. Diabetes Care 2003; 26: 12511257.
  • 13
    Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008; 121: 7278.
  • 14
    Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. HEPATOLOGY 2003; 37: 917923.
  • 15
    Amarapurka DN, Amarapurkar AD, Patel ND, Agal S, Baigal R, Gupte P, et al. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Ann Hepatol 2006; 5: 3033.
  • 16
    Angulo P, Hui JM, Marchesini G, Bugianesi E, Jeorge J, Farrell GC, et al. The NAFLD fibrosis score :a non invasive system that identified liver fibrosis in patients with NAFLD. HEPATOLOGY 2007; 45: 846854.
  • 17
    Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. HEPATOLOGY 2003; 37: 12861292.
  • 18
    Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, et al. Prevalence of risk factors of non-alcoholic fatty liver disease in potential living donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007; 47: 239244.
  • 19
    Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 19.
  • 20
    Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 31433421.
  • 21
    Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20: 10871092.
  • 22
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 24672474.
    Direct Link:
  • 23
    Kleiner DE, Brunt EM, Natta MV, Behling C, Contos M, Cimming OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 13131321.
  • 24
    Gaidos JKJ, Hillner BE Sanyal AJ. A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis. Liver Int 2008; 28: 650658.
  • 25
    Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 18981906.
  • 26
    Rousselet MC, Michalak S, Dupre F, Croue A, Bedosa P, Saint-André JP, et al. Source of variability in histological scoring of chronic viral hepatitis. HEPATOLOGY 2005; 41: 257264.
  • 27
    Machado M, Vidal PM, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45: 600606.
  • 28
    Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler P. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007; 102: 399408.
    Direct Link:
  • 29
    Dongiovanni P, Valenti L, Ludovica Fracanzani A, Gatti S, Cairo G, Fargion S. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol 2008; 172: 738747.
  • 30
    Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007; 102: 12511258.
    Direct Link:
  • 31
    Jepsen P, Vilstrup H, Mellemkjaer L, Thulstrup AM, Olsen JH, Baron JA, et al. Prognosis of patients with a diagnosis of fatty liver-a registry-based cohort study. Hepatogastroenterology 2003; 50: 21012104.
  • 32
    Ong JP, Pitts A, Younossi ZM. Non-alcoholic fatty liver disease (NAFLD) is associated with higher overall mortality and liver related mortality. J Hepatol 2008; 48( Suppl 2): S5.
  • 33
    Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54: 35413546.
  • 34
    Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006; 29: 13251330.